Cookies ensure the smooth running of our services. Using Univadis, you accept the use of cookies. Learn more.

Univadis - a service form MSD

A trusted medical reference

Create an account Log in

app catalog Search

Log in

Close

My Account

Loading...

Medical News Image & Media Library Delete Medical Quiz PubMed Delete Oncology Delete Hepatitis C Delete Conference Reports Radiology Collection Delete eLearning Link Library Delete Lausunto- ja lomakepohjat Patient Resource Centre HCV Journals Delete Calendar Vaccinal Delete Rokottaminen Delete HIV Delete Explore new apps

See all my apps Hide my apps

Explore new apps Manage my apps

Rearrange your apps by dragging them or delete them with the cross.

Save Cancel

Welcome. Please log in or create an account.

Log in

Remember me (Uncheck if on a shared computer)

Forgot your password ?

Please review the fields marked in red and resubmit the form

Create an account

Register to access independent medical news and resources from Univadis^®

Latest updates

Medical News

Favourable trends for major neoplasms are predicted to continue, except for pancreatic cancer.

1.4 million cancer deaths predicted in EU in 2019

Univadis Medical News
22 March 2019

Favourable trends for major neoplasms are predicted to continue, except for pancreatic cancer.

The review has been initiated following the recent publication of new information on screening for DPD deficiency.

EMA starts review of fluorouracil and related drugs

Univadis Medical News
22 March 2019

The review has been initiated following the recent publication of new information on screening for DPD deficiency.

The Committee also agreed that it is irresponsible at this time for anyone to proceed with clinical applications of human germline genome editing.

Expert panel calls for central registry on human genome editing research

Univadis Medical News
22 March 2019

The Committee also agreed that it is irresponsible at this time for anyone to proceed with clinical applications of human germline genome editing.

The Lancet Commission on TB has recommended five key priority investments to achieve this.

Lancet Commission sets targets to eliminate TB within a generation

Univadis Medical News
22 March 2019

The Lancet Commission on TB has recommended five key priority investments to achieve this.

Findings from a post hoc analysis of the REACT trial.

Crohn’s disease: immunosuppression for older patients

Univadis Medical News
21 March 2019

Findings from a post hoc analysis of the REACT trial.

More Medical News >

Conference Reports

CROI 2019—Bictegravir/FTC/TAF pill well-tolerated in children, adolescents

Conference Reports
13 March 2019

Youth tolerate adult dose.

CROI 2019—Early neonatal ART leads to faster HIV suppression

Conference Reports
13 March 2019

Each week of delay made early suppression less likely.

CROI 2019—F/TAF noninferior to F/TDF for HIV PrEP in DISCOVER

Conference Reports
13 March 2019

New option could be safer than F/TDF formulation.

More Conference Reports >

Featured channels

application icon

HIV All you need to know about HIV

application icon

Rokottaminen Vaccination essentials all in one place

application icon

Hepatitis C The Essentials selected for you

application icon

Oncology Oncology essentials all in one place

Keep up with oncology literature in minutes, every day

Get your daily dose of the latest evidence published in your cancer area of practice
Get my daily Newsletter

Univadis^®

Univadis^®, provided by MSD, brings you unbiased, relevant medical news as well as helpful resources for your daily practice at no cost.

Our Partners

Univadis^® brings together premium content publishers that deliver comprehensive and up-to-date medical information.

Contact Us

E-mail Us

Complete contact form >

MSD does not endorse and is not responsible for the accuracy of the content, or for practices or standards of non-MSD sources. Please read our Terms of Use for more information

Privacy Policy | Transparency Policy

Copyright © 2019 Merck Sharp & Dohme Corp., Finland is a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved.